Key Takeaways
- Confluence Genetics has acquired the business assets of Benson Hill through a bankruptcy court-approved sale.
- The acquisition was led by Expedition Ag Partners and S2G Investments, forming a new agtech-focused entity.
- The company aims to expand its ultra-high protein soybean genetics and specialty food-grade soy portfolio.
- Over 350 patents and a proprietary AI-driven platform will support future R&D and commercialization.
- Kim Hurst named CEO; Mike DeCamp appointed Executive Chairman of the Board.
Confluence Genetics Begins New Chapter with Benson Hill Acquisition
The United States Bankruptcy Court for the District of Delaware has officially approved the sale of Benson Hill’s business assets to Confluence Genetics, LLC. The transaction, which closes at 11:59 p.m. on the 23rd of May, concludes Benson Hill’s Chapter 11 restructuring and initiates operations for the company under new ownership and leadership.
This transfer marks a strategic transition for the soybean genetics business, setting the foundation for the company to continue operations with a more focused mission and a reduced cost structure.
Confluence Genetics Outlines Strategic Vision for Growth
Confluence Genetics emerges as a new agtech enterprise backed by a consortium of agribusiness investors, primarily Expedition Ag Partners and S2G Investments. The company’s immediate focus will be on scaling its proprietary ultra-high protein soybean varieties, growing its food-grade soy portfolio, and entering new geographies.
CEO Kim Hurst highlighted the company’s commitment to innovation: “With our proprietary genetics, CropOS® technology platform, and state-of-the-art speed breeding facility, we will deliver high-value, differentiated, quality trait soybeans.”
The firm plans to utilize AI-based breeding and speed breeding capabilities to accelerate the development and commercialization of new soybean traits.
To Leverage Technology and IP Portfolio
Included in the acquisition are over 350 patents, issued or pending, that will provide a strong intellectual property base for Confluence Genetics. Among the highlights is the 2029 soybean class, planted in 2025 field trials, which is expected to exhibit enhanced traits such as higher protein content and improved oil profiles.
This genetic portfolio aligns with the company’s aim to deliver traits that are valuable throughout the supply chain—from growers to processors and end users.
Leadership Support and Industry Outlook for Confluence Genetics
Mike DeCamp, President and CEO of Expedition Ag Partners, will serve as Executive Chairman of the Board at Confluence Genetics. Having led the Debtor-In-Possession financing, DeCamp emphasized the long-term growth prospects of the newly formed company.
“Confluence Genetics has the right tools, talent, and technology to shape soy innovation in ways that we’re only beginning to appreciate,” said DeCamp.
Both DeCamp and Hurst bring extensive experience in agribusiness, which will be instrumental in steering Confluence Genetics through its next phase.
